Vertex Finally Inks Orkambi Deal In England

Stalemate Over As Parties Agree Deal That Also Includes Symkevi And Kalydeco

Vertex has finally managed to reach an agreement to bring its cystic fibrosis drugs Orkambi and Symkevi to patients in England, which constitutes an important slice of what is the second biggest market for the drugs.

Cystic Fibrosis, Medical Concept with Pills, Injections and Syringe. Cystic Fibrosis - Printed Diagnosis with Blurred Text. 3D Render.
• Source: Shutterstock

The stalemate between NHS England and Vertex Pharmaceuticals Inc. over the cystic fibrosis drug Orkambi (lumacaftor/ivacaftor) is finally over. The two parties have finally agreed a deal that will give the company better access to the UK, the second biggest market for its cystic fibrosis drugs which also include Symkevi (tezacaftor/ivacaftor) and Kalydeco (ivacaftor).

Under the deal announced on 24 October, patients will have access to Orkambi and Symkevi in all current and future...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Business

More from Scrip